Carlson Caspers is a law firm that publishes detailed legal analyses primarily focused on intellectual property law, including patent litigation and regulatory issues related to pharmaceuticals and biotechnology. Their blog covers court decisions, appellate rulings, and regulatory interpretations affecting patent enablement, written description requirements, and patent listing in the FDA's Orange Book. The firm provides insights into complex legal standards such as the enablement requirement under Section 112 of the Patent Act, patent infringement defense costs, and challenges to patent listings. Their content is relevant for legal professionals, pharmaceutical companies, and entities involved in patent prosecution and litigation, especially in the context of ANDA cases and biosimilar products.